Chau Dang, MD
Memorial Sloan Kettering Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Chau Dang, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:56 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT03377387 · Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast CancerMemorial Sloan Kettering Cancer Center · completed · Breast Cancer · principal investigator
- Ph2NCT02252887 · Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based TherapyMemorial Sloan Kettering Cancer Center · completed · Metastatic HER2-Positive Breast Cancer · principal investigator
- Ph2NCT01827163 · Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast CancerMemorial Sloan Kettering Cancer Center · completed · HER2-Positive Early Stage Breast Cancer · principal investigator
- Ph2NCT01276041 · Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast CancerMemorial Sloan Kettering Cancer Center · completed · Breast Cancer · principal investigator
- N/ANCT00617370 · Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: FeasibilityMemorial Sloan Kettering Cancer Center · completed · Breast Cancer, Adenocarcinoma of the Breast · principal investigator
- Ph2NCT00591851 · Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: FeasibilityMemorial Sloan Kettering Cancer Center · completed · Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:56 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in breast cancer.